Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity

Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows

This article from Verge's Optimizer newsletter examines how health tech companies are marketing products specifically to GLP-1 drug users (p

Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption

This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica

Conflicts of interest threaten integrity of GLP-1 therapy guidance, experts warn

This article discusses the risks of conflicts of interest in clinical guidance for GLP-1 receptor agonists (like Ozempic, Wegovy) used for o

Eli Lilly's experimental GLP-1 drug achieves 28% average weight loss, raising safety questions

Eli Lilly has released data showing its experimental GLP-1 weight-loss drug enables patients to lose an average of 28% of their body weight,

GLP-1 Prescriptions Rise as U.S. Obesity Rates Show Modest Decline, New Data Indicates

New data from EPIC Research shows that GLP-1 medications like Ozempic and Wegovy are having a population-wide impact on obesity rates. As pr